Johnson & Johnson reported strong first-quarter results with sales and adjusted EPS exceeding expectations, driven by robust growth in the pharmaceuticals segment. Management provided optimistic guidance and emphasized strategic investments and cost-saving measures, despite minor setbacks in the medical devices division. The positive performance and confident outlook are likely to bolster investor sentiment in the short term.

[1]